Advertisement
Screener

GSK plc (GLAXF) Form 6-K: Report of foreign private issuer, 2023

2.1 / 5 stars · 17/40 Roast Me

Add as a preferred source on Google

GSK plc Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2023-12-21: Form 6-K; Period of report 2023-12-21; Description DIRECTOR/PDMR SHAREHOLDING; Document a6513x.htm.
  • 2023-12-18: Form 6-K; Period of report 2023-12-18; Description JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT; Document a1192x.htm.
  • 2023-12-13: Form 6-K; Period of report 2023-12-13; Description DIRECTOR/PDMR SHAREHOLDING; Document a6545w.htm.
  • 2023-12-12: Form 6-K; Period of report 2023-12-11; Description JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS; Document a3878w.htm.
FiledFormPeriod of reportDescriptionDocument
2023-12-216-K2023-12-21DIRECTOR/PDMR SHAREHOLDINGa6513x.htm
2023-12-186-K2023-12-18JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINTa1192x.htm
2023-12-136-K2023-12-13DIRECTOR/PDMR SHAREHOLDINGa6545w.htm
2023-12-126-K2023-12-11JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTSa3878w.htm
2023-12-116-K2023-12-11JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATIONa2250w.htm
2023-12-046-K2023-12-04GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATESa6068v.htm
2023-12-016-K2023-12-01TOTAL VOTING RIGHTSgsk4340v.htm
2023-11-306-K2023-11-30BLOCK LISTING APPLICATIONa1078v.htm
2023-11-296-K2023-11-29HOLDING(S) IN COMPANYa6kcovergsk.htm
2023-11-276-K2023-11-27GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTSa6764u.htm
2023-11-216-K2023-11-21DIRECTOR/PDMR SHAREHOLDINGa1604u.htm
2023-11-156-K2023-11-15BLOCK LISTING INTERIM REVIEWa4518t.htm
2023-11-136-K2023-11-13DIRECTOR/PDMR SHAREHOLDINGa2740tgskedgar.htm
2023-11-136-K2023-11-13GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIBa2099t.htm
2023-11-016-K2023-11-01TOTAL VOTING RIGHTSa0855s.htm
2023-11-016-K2023-11-013RD QUARTER RESULTSa9554r.htm
2023-10-306-K2023-10-30JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINTa6268r.htm
2023-10-266-K2023-10-26NMPA APPROVES VOCABRIA+REKAMBYS IN CHINAa3337rgskplcedgar.htm
2023-10-256-K2023-10-25DIRECTOR/PDMR SHAREHOLDINGa2947r.htm
2023-10-256-K2023-10-25NEW DATA FOR AREXVY, GSK'S RSV VACCINEa1783rgskedgar.htm
2023-10-206-K2023-10-20DIRECTOR/PDMR SHAREHOLDINGa8420q-gskplc.htm
2023-10-186-K2023-10-18DIRECTOR/PDMR SHAREHOLDINGa5642q-gskplc.htm
2023-10-176-K2023-10-17DIRECTOR/PDMR SHAREHOLDINGa4185q.htm
2023-10-166-K2023-10-16JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINIONa1976q.htm
2023-10-136-K2023-10-13DIRECTOR/PDMR SHAREHOLDINGa1179q.htm
2023-10-126-K2023-10-12DIRECTOR/PDMR SHAREHOLDINGa9743p.htm
2023-10-116-K2023-10-11ZANTAC (RANITIDINE) LITIGATIONa7221p.htm
2023-10-106-K2023-10-10GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIPa0542p.htm
2023-10-066-K2023-10-06GSK COMPLETES SALE OF SHARES IN HALEON PLCa9069o.htm
2023-10-066-K2023-10-06CURRENT REPORTgsk-6k_100623.htm
2023-10-026-K2023-10-02TOTAL VOTING RIGHTSa3970o.htm
2023-09-276-K2023-09-27DIRECTORATE CHANGEa8766n.htm
2023-09-256-K2023-09-25GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPANa5033n.htm
2023-09-216-K2023-08-21DIRECTOR/PDMR SHAREHOLDINGa2643n.htm
2023-09-196-K2023-09-19APRETUDE FOR PREP RECEIVES EMA APPROVALa8334m.htm
2023-09-186-K2023-09-18FDA APPROVES OJJAARA (MOMELOTINIB)a7255m.htm
2023-09-136-K2023-09-13DIRECTOR/PDMR SHAREHOLDINGa3518m.htm
2023-09-116-K2023-09-11DIRECTOR/PDMR SHAREHOLDINGa0591m.htm
2023-09-116-K2023-09-11MOMELOTINIB FILING ACCEPTED IN JAPANa9383l.htm
2023-09-066-K2023-09-06DIRECTOR/PDMR SHAREHOLDINGa6072l.htm
2023-09-016-K2023-09-01TOTAL VOTING RIGHTSa1261l.htm
2023-09-016-K2023-09-01GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPANa0257l.htm
2023-08-316-K2023-08-31HOLDING(S) IN COMPANYa0033l.htm
2023-08-316-K2023-08-31HOLDING(S) IN COMPANYa0022l.htm
2023-08-256-K2023-08-25DIRECTOR/PDMR SHAREHOLDINGa5139k.htm
2023-08-236-K2023-08-23DIRECTOR/PDMR SHAREHOLDINGa2500k.htm
2023-08-236-K2023-08-23SHINGRIX DATA DEMONSTRATE 100% EFFICACY IN CHINAa1343k.htm
2023-08-226-K2023-08-22DIRECTOR/PDMR SHAREHOLDINGa1179k.htm
2023-08-106-K2023-08-10DIRECTOR/PDMR SHAREHOLDINGa9820i.htm
2023-08-096-K2023-08-09DIRECTOR/PDMR SHAREHOLDINGa8335i.htm
2023-08-016-K2023-08-01TOTAL VOTING RIGHTSa9336h.htm
2023-07-316-K2023-07-31FDA APPROVES NEW USE FOR JEMPERLI PLUS CHEMOa8071h.htm
2023-07-316-K2023-07-31DIRECTOR/PDMR SHAREHOLDINGa7732h.htm
2023-07-286-K2023-07-28DIRECTOR/PDMR SHAREHOLDINGa6141h.htm
2023-07-266-K2023-07-262ND QUARTER RESULTSa1738h-gsk2.htm
2023-07-246-K2023-07-24CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMPa8706g.htm
2023-07-206-K2023-07-20DIRECTOR/PDMR SHAREHOLDINGa7041g.htm
2023-07-176-K2023-07-17DIRECTOR/PDMR SHAREHOLDINGa2655g.htm
2023-07-136-K2023-07-13DIRECTOR/PDMR SHAREHOLDINGa9694f.htm
2023-07-036-K2023-07-03TOTAL VOTING RIGHTSa7977e.htm
2023-06-286-K2023-06-28GSK COMPLETES ACQUISITION OF BELLUS HEALTHa2788e.htm
2023-06-276-K2023-06-27FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATEa9661d.htm
2023-06-266-K2023-06-26GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINIONa8139d.htm
2023-06-266-K2023-06-26SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVERa7913d.htm
2023-06-236-K2023-06-23DIRECTOR/PDMR SHAREHOLDINGa7867d.htm
2023-06-236-K2023-06-23DIRECTOR/PDMR SHAREHOLDINGa7869d.htm
2023-06-236-K2023-06-23DIRECTOR/PDMR SHAREHOLDINGa7862d.htm
2023-06-236-K2023-06-23STATEMENT: ZANTAC (RANITIDINE) LITIGATIONa7198d.htm
2023-06-226-K2023-06-22GSKS AREXVY RECOMMENDED BY ACIPa5318d.htm
2023-06-216-K2023-06-21SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINEa3715d.htm
2023-06-166-K2023-06-16EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIBa9217c.htm
2023-06-126-K2023-06-12DIRECTOR/PDMR SHAREHOLDINGa4444c.htm
2023-06-076-K2023-06-07EU AUTHORISATION OF GSKS RSV VACCINE AREXVYa8777b.htm
2023-06-066-K2023-06-06GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLIa7294b.htm
2023-06-016-K2023-06-01TOTAL VOTING RIGHTSa2118b.htm
2023-05-226-K2023-05-22DIRECTOR/PDMR SHAREHOLDINGa2125a.htm
2023-05-156-K2023-05-15DIRECTOR/PDMR SHAREHOLDINGa4640z.htm
2023-05-156-K2023-05-15BLOCK LISTING INTERIM REVIEWa3421z.htm
2023-05-126-K2023-05-12DIRECTOR/PDMR SHAREHOLDINGa3108z.htm
2023-05-126-K2023-05-12MENABCWY VACCINE PRELIMINARY PHASE III RESULTSa2504z.htm
2023-05-126-K2023-05-12STATEMENT: ZANTAC LITIGATION UPDATE BC CANADAa1830z.htm
2023-05-126-K2023-05-12GSK COMPLETES SALE OF SHARES IN HALEON PLCa1918z.htm
2023-05-126-K2023-05-11CURRENT REPORT OF FOREIGN ISSUERgsk_6k-0523.htm
2023-05-096-K2023-05-09DIRECTOR/PDMR SHAREHOLDINGa8207y.htm
2023-05-046-K2023-05-04DIRECTOR/PDMR SHAREHOLDINGa4515y.htm
2023-05-036-K2023-05-03RESULT OF AGMa3372y.htm
2023-05-036-K2023-05-03US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTSa3355y.htm
2023-05-026-K2023-05-02TOTAL VOTING RIGHTSa9376x.htm
2023-04-286-K2023-04-28DIRECTOR/PDMR SHAREHOLDINGa9477x.htm
2023-04-276-K2023-04-27GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINIONa6175x.htm
2023-04-266-K2023-04-261ST QUARTER RESULTSa4488x.htm
2023-04-256-K2023-04-25EMA VALIDATES JEMPERLI FILING FOR NEW INDICATIONa2960x.htm
2023-04-206-K2023-04-20DIRECTOR/PDMR SHAREHOLDINGa8883w.htm
2023-04-196-K2023-04-19DIRECTOR/PDMR SHAREHOLDINGa8013w.htm
2023-04-186-K2023-04-18GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INCa5635w.htm
2023-04-176-K2023-04-17DIRECTOR/PDMR SHAREHOLDINGa4697w.htm
2023-04-176-K2023-04-17GEPOTIDACIN POSITIVE PHASE III DATAa3459w.htm
2023-04-036-K2023-04-03TOTAL VOTING RIGHTSa1056v.htm
2023-03-286-K2023-03-28POSITIVE PHASE III RUBY RESULTS FOR JEMPERLIa3880u.htm
2023-03-276-K2023-03-27PUBLICATION OF 2023 AGM NOTICEa3441u.htm
Advertisement